A PHASE 1 SINGLE ASCENDING DOSE STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACODYNAMIC EFFECTS OF MDK-703, AN IL-7 MIMETIC WITH EXTENDED HALF-LIFE

被引：2
|
作者：
Friend, Richard [1 ]
Baxter, Bryan [2 ]
Park, Inkyung Angie [2 ]
Cwirla, Steven [2 ]
Barrett, Ronald [2 ]
机构：
[1] Nucleus Network Pty Ltd, Herston, Qld, Australia
[2] Medikine, Menlo Pk, CA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0625
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
625
引用
收藏
页码：A657 / A657
页数：1
相关论文
共 50 条
  • [1] A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB002, an Anti-TNFα mAb Designed for Extended Half-life, in Healthy Volunteers
    Sellwood, Cory
    Gao, Minggeng
    Matijevic, Mark
    Wax, Stephen
    Yamashita, Mason
    Yu, Shan
    Arora, Sujata
    Kirk, Rachel
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4534 - 4535
  • [2] A phase 1 single ascending dose study of the safety, tolerability and pharmacokinetics of CRV431
    Armas, Danielle
    Snyder, Michael
    Trepanier, Daniel
    Ure, Daren
    Greytok, Jill
    Foster, Robert
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E464 - E465
  • [3] A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB004, a CTLA-4-Ig Fusion Protein Designed for Increased Binding Affinity and Extended Half-life, in Healthy Volunteers
    Sellwood, Cory
    Gao, Minggeng
    Zhang, Sheen
    Matijevic, Mark
    Wax, Stephen
    Yamashita, Mason
    Yu, Shan
    Arora, Sujata
    Kirk, Rachel
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4535 - 4536
  • [4] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Naloxegol at Peripheral and Central Nervous System Receptors in Healthy Male Subjects: A Single Ascending-Dose Study
    Eldon, Michael A.
    Kugler, Alan R.
    Medve, Robert A.
    Bui, Khanh
    Butler, Kathleen
    Sostek, Mark
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (06): : 434 - 441
  • [5] A phase 1, ascending dose study to assess the potential effects of trofinetide on QTc interval, safety and tolerability, and pharmacokinetics in healthy adults
    Darwish, M.
    Harlick, J.
    Youakim, J.
    DeKarske, D.
    Stankovic, S.
    ANNALS OF NEUROLOGY, 2022, 92 : S174 - S174
  • [6] Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers
    Merica, VarshaIyer Elizabeth
    Ronseaux, Sebastien
    Gamache, Tressa
    Mulrow, Nancy J.
    Belcijan, Anja
    Callaghan, Michael U.
    BLOOD, 2021, 138
  • [7] Phase 1b single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of HT-100 in DMD
    Escolar, D. M.
    Davis-Golden, J.
    Loewy, J.
    Bush, E.
    Dykstra, K.
    Blaustein, M.
    NEUROMUSCULAR DISORDERS, 2013, 23 (9-10) : 802 - 803
  • [8] Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
    Domachowske, Joseph B.
    Khan, Anis A.
    Esser, Mark T.
    Jensen, Kathryn
    Takas, Therese
    Villafana, Tonya
    Dubovsky, Filip
    Griffin, M. Pamela
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2018, 37 (09) : 886 - 892
  • [9] A phase 1, single and fractionated, ascending dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietic mimetic antibody fusion protein, CNT0528, in healthy male subjects
    Franson, KL
    Burggraaf, J
    Bouman-Trio, EA
    Cohen, AF
    Miller, BE
    Jang, H
    Marciniak, SJ
    van de Ketterij, EPS
    Frederick, B
    Jiao, Q
    Getsy, J
    Bald, EH
    Walker, H
    Schantz, A
    Ford, JA
    Mascioli, K
    Kowalchick, JB
    BLOOD, 2005, 106 (11) : 151B - 151B
  • [10] A phase 1, single ascending dose study evaluating the safety, pharmacokinetics and pharmacodynamics of subcutaneous administration of an erythropoeitic mimetic antibody fusion protein (CNTO 528) in healthy male subjects.
    Bouman-Thio, E.
    Franson, K.
    Burggraaf, J.
    Cohen, A.
    Miller, B.
    Bai, S.
    Marcimak, S.
    Yohrling, J.
    Jiao, T.
    Shankar, G.
    Ramani, K.
    Marini, J. C.
    Pendley, C.
    Ford, J.
    Kowalchick, J.
    Bald, E.
    Frigo, M.
    Frederick, B.
    Walker, H.
    Schantz, A.
    Getsy, J.
    Davis, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S95 - S95
12345